Skip to main content
ArticleOPEN ACCESS

Commentary: Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in squamous cell carcinoma of the head and neck (MEHGAN Study)

Frontiers in Oncology
DOI: 10.3389/fonc.2017.00031
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Author supplied keywords

Cite

CITATION STYLE

APA

Saba, N. F. (2017, March 13). Commentary: Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in squamous cell carcinoma of the head and neck (MEHGAN Study). Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2017.00031

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free